Irsogladine

DB13056InvestigationalSmall molecule

Irsogladine is under investigation in clinical trial NCT02581696 (The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers).

Mechanism: Pharmacologically active on Phosphodiesterase 4
Curator reviewed
Formula / weight: C₉H₇Cl₂N₅ · 256.09 g/mol (avg)

Resolves to

Compound

UNIIQBX79NZC1DCAS57381-26-7ChEMBLCHEMBL136497ChEBI93307PubChem3752

Clinical / RWD

ATCA02BX16

Structure

InChIKeyATCGGEJZONJOCL-UHFFFAOYSA-NSMILESNC1=NC(=NC(N)=N1)C1=C(Cl)C=CC(Cl)=C1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 9 drug categories

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Irsogladine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account